Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab

Portal hypertension (PHT) often complicates hepatocellular carcinoma (HCC) treatment and prognosis. We aimed to assess PHT's impact on AtezoBev outcomes and identify predictors of acute variceal bleeding (AVB) and clinical ascites occurrence.

Source: Digestive and Liver Disease - March 27, 2024 Category: Gastroenterology Authors: Philippe Sultanik, Claudia Campani, Edouard Larrey, Bertille Campion, Manon Evain, Charles Roux, Lorraine Blaise, Mathilde Wagner, Marika Rudler, Jean Charles Nault, Dominique Thabut, Manon Allaire Tags: Oncology Source Type: research